FDA Aims For Flexibility In Upcoming Drug/Companion Diagnostic Guidance
Executive Summary
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed
You may also be interested in...
Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
The molecularly targeted oncologics that have energized oncology drug development and treatment over the last decade have sparked a secondary boom in companion diagnostics. After all, a drug for a tumor expressing a particular receptor profile is not particularly useful unless physicians can identify patients with that profile.
Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
The molecularly targeted oncologics that have energized oncology drug development and treatment over the last decade have sparked a secondary boom in companion diagnostics. After all, a drug for a tumor expressing a particular receptor profile is not particularly useful unless physicians can identify patients with that profile.
Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
The molecularly targeted oncologics that have energized oncology drug development and treatment over the last decade have sparked a secondary boom in companion diagnostics. After all, a drug for a tumor expressing a particular receptor profile is not particularly useful unless physicians can identify patients with that profile.